2673196-38-6
Chemical Structure
JAK3/BTK-IN-4
- CAS No.: 2673196-38-6
- Formula:C21H25ClN8O
- Molecular Weight:440.93
IUPAC Name: 1-(1-(5-chloro-2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.5]nonan-6-yl)prop-2-en-1-one
InChIKey: UEQJTAASROYNBA-UHFFFAOYSA-N
SMILES: C=CC(N(CCC1)CC21CCN2C3=C4C(NC=C4Cl)=NC(NC5=CN(CC)N=C5)=N3)=O
Biological Activity: JAK3/BTK-IN-4 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-4 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 003)[1]
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
JAK3/BTK-IN-4 | JAK3/BTK-IN-4 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-4 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 003) | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
